Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives
Léa El Haddad,Mainur Khan,Rania Soufny,David Mummy,Bastiaan Driehuys,Wissam Mansour,Priya S Kishnani,Mai K ElMallah
DOI: https://doi.org/10.2147/TCRM.S362871
2023-09-02
Therapeutics and Clinical Risk Management
Abstract:Léa El Haddad, 1 Mainur Khan, 1 Rania Soufny, 1 David Mummy, 2 Bastiaan Driehuys, 2 Wissam Mansour, 3 Priya S Kishnani, 4 Mai K ElMallah 1 1 Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA; 2 Department of Radiology, Duke University Medical Center, Durham, NC, USA; 3 Division of Pulmonary and Sleep Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA; 4 Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA Correspondence: Mai K ElMallah, Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Duke University Medical Center, Box 2644, Durham, NC, 27710, USA, Tel +1-919-684-3577, Email Pompe disease (PD) is a neuromuscular disorder caused by a deficiency of acid alpha-glucosidase (GAA) – a lysosomal enzyme responsible for hydrolyzing glycogen. GAA deficiency leads to accumulation of glycogen in lysosomes, causing cellular disruption. The severity of PD is directly related to the extent of GAA deficiency – if no or minimal GAA is produced, symptoms are severe and manifest in infancy, known as infantile onset PD (IOPD). If left untreated, infants with IOPD experience muscle hypotonia and cardio-respiratory failure leading to significant morbidity and mortality in the first year of life. In contrast, late-onset PD (LOPD) patients have more GAA activity and present later in life, but also have significant respiratory function decline. Despite FDA-approved enzyme replacement therapy, respiratory insufficiency remains a major cause of morbidity and mortality, emphasizing the importance of early detection and management of respiratory complications. These complications include impaired cough and airway clearance, respiratory muscle weakness, sleep-related breathing issues, and pulmonary infections. This review aims to provide an overview of the respiratory pathology, monitoring, and management of PD patients. In addition, we discuss the impact of novel approaches and therapies on respiratory function in PD. Keywords: Pompe disease, respiratory complications, respiratory monitoring, respiratory therapy Pompe disease (PD), or glycogen storage disease type II, is an autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA) - an enzyme responsible for hydrolyzing lysosomal glycogen. 1 PD is a neuromuscular disorder characterized by systemic lysosomal glycogen accumulation causing diffuse cellular disruption in muscles and motor neurons. PD encompasses a broad spectrum of disease severity ranging from severe infantile-onset to late-onset Pompe disease (IOPD and LOPD, respectively). The classification of PD is determined by the age at diagnosis, amount of the residual GAA enzyme activity, and cardiac involvement. 2,3 In untreated infants with IOPD, symptoms can manifest at birth or in the first few weeks of life. These symptoms include muscle hypotonia, cardiomegaly, and respiratory decline, ultimately leading to cardiorespiratory failure and death within the first 2 years of life. 2 On the other hand, LOPD can present at various ages, ranging from early childhood to adulthood. A key distinguishing feature of LOPD is the absence of cardiomyopathy in the first year of life. 2 To date, the only FDA-approved treatment for PD is enzyme replacement therapy (ERT) with human recombinant GAA (rhGAA). rhGAA breaks down the excess glycogen in the lysosomes and improves muscle function. A meta-analysis performed on the efficacy of ERT in patients with LOPD revealed a significantly improved walking distance on the six-minute walk test. 4 However, the respiratory function and muscle strength in these patients remained unchanged. 4 In contrast, other studies have shown stable respiratory function and improved motor function with ERT in LOPD patients. 5 Similarly, increased ventilator-free survival is seen in IOPD patients. 6 Despite improved clinical outcomes in patients treated with ERT, the clinical response to ERT varies considerably between patients due to many factors including age, stage of treatment, dose of ERT, the Cross-Reactive Immunological Material (CRIM) status, and muscle fiber type. 7,8 CRIM-positive (CRIM+) patients produce some residual but nonfunctional GAA enzyme and better tolerate ERT. They typically have low neutralizing antibody titers against rhGAA, making the treatment effective. On the other hand, CRIM negative (CRIM-) patients are unable to produce any GAA protein and generally do not tolerate ERT because of a significant immune response against rhGAA resulting in respiratory decline, ventilator dependence, and -Abstract Truncated-
health care sciences & services